Malignant placental site trophoblastic tumor associated with placental abruption, fetal distress, and elevated CA-125 by Hopkins, Michael P. et al.
GYNECOLOGIC ONCOLOGY 47, 267-271 (1992) 
CASE REPORT 
Malignant Placental Site Trophoblastic Tumor Associated with Placental 
Abruption, Fetal Distress, and Elevated CA-l 25 
MICHAEL P. HOPKINS, M.D.,*.’ CHARLES W. DRESCHER, M.D.,* ANNE MCQUILLAN, M.D. ,t JOHN KEYSER, M.D. ,$ 
AND ROBERT SCHMIDT, M.D.7 
Departments of *Obstetrics & Gynecology and tfathology, University of Michigun Medical Center, Ann Arbor, Michigan; 
und $Port Huron Hospital, Port Huron, Michigan 
Received February 12, 1992 
The second pregnancy of 27-year-old woman, gravida 2, para 
2 was complicated by a low cY-fetoprotein and symptoms of 
chronic placental abruption. She delivered by cesarean section at 
35 weeks for fetal distress at which time a biopsy of the uterus 
revealed a placental site trophoblastic tumor (PSTT). She rapidly 
developed intraabdominal spread of the neoplasm which did not 
respond to chemotherapy and she died 10 weeks later. Her CA- 
125 was elevated to 5360 u/ml and this decreased after hyster- 
ectomy. This patient is reported to highlight a very malignant 
course of PSTT that was associated with a live-born male infant. 
cc, 1992 Academic Press, Inc. 
INTRODUCTION 
Placental site trophoblastic tumor (PSTT) was de- 
scribed in 1976 as a probably benign tumor [l]. Initially 
called pseudotrophoblastic tumor, reports of 10 patients 
with metastases who succumbed to their disease have led 
to a different philosophy concerning the benign course of 
this tumor. Thus, it is currently called placental site tro- 
phoblastic tumor [2-121. The PSTI is thought to arise 
from the placental implantation site. It is usually diag- 
nosed at some interval after pregnancy, and it is most 
frequently associated with what is thought to be a spon- 
taneous abortion. There has been only 1 case reported 
in which PSIT was diagnosed in conjunction with a po- 
tentially viable fetus. This patient, reported by Finkler et 
ul., was at 21 weeks estimated gestational age when she 
spontaneously lost the pregnancy [5]. Recently we treated 
a patient with PSTT who was diagnosed at cesarean sec- 
’ To whom reprint requests should be addressed at Northeastern Ohio 
Universities College of Medicine, 400 Wabash Avenue, Akron, Ohio 
44307. 
tion performed for placental abruption. The patient is 
being reported on in detail to highlight the malignant 
course of her PSTT and the previously unreported as- 
sociation of this disease with a viable pregnancy and an 
elevated serum CA-125. 
CASE REPORT 
N.K., a 27-year-old, gravida 2, para 2 woman, delivered 
her first child, a normal female, by low transverse cesar- 
ean section for failure to progress 2 years prior to the 
present pregnancy. Her uterus and placenta were normal 
at that time and her postoperative course was unremark- 
able. Normal regular menses resumed after the first preg- 
nancy. She conceived again 2 years later without difficulty 
and was initially seen at 8 weeks estimated gestational 
age. Pelvic examination was appropriate for gestational 
age and routine prenatal laboratory studies were normal. 
An a-fetoprotein performed at 14 weeks was 10.2 IU/ml, 
which was 0.4 multiples of the median (normal range, 0.5 
to 2.2 multiples of the median). After full genetic con- 
sultation the patient underwent an amniocentesis. The 
amniocentesis showed a normal 46XY karyotype. Ultra- 
sound at the time of amniocentesis was normal and the 
posterior placenta appeared normal. The pregnancy pro- 
ceeded uneventfully until 30 weeks estimated gestational 
age when the patient began to experience vaginal bleeding 
and cramping. An ultrasound at this time showed a pos- 
terior echogenic area in the region of the cervix thought 
to be a fibroid. Over the next 5 weeks, she experienced 
intermittent fevers to approximately 39°C. She was also 
admitted three times for bleeding. The diagnosis of a 
small but chronic abruption was made based on the clin- 
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ical parameters. No etiology for the fever could be de- 
termined. At 35 weeks estimated gestational age, the pa- 
tient was admitted with increasing uterine contractions 
and vaginal bleeding. Biophysical profile disclosed oh- 
gohydramnios and evidence for fetal distress. The patient 
was delivered by emergency vertical cesarean section of 
a live-born male weighing 5 lb. 8 oz. He is now 24 months 
old and normal. The uterus appeared thickened and ab- 
normal with a “cardboard-like appearance” at the time 
of delivery. A myometrial biopsy showed PSTT. 
The patient’s postoperative course was unremarkable 
for the first 4 days. She then began to have daily tem- 
perature elevations to 39-40°C. She did not respond to 
penicillin, gentamycin, and clindamycin antibiotic ther- 
apy. A CAT scan suggested an abscess. Surgical reex- 
ploration disclosed that only peritoneal fluid and cultures 
were negative. No abscess was identified at this time. The 
patient continued to have an elevated baseline temper- 
ature at approximately 38°C with nightly temperature el- 
evations to 39-40°C. Intravenous heparin was added to 
the antibiotic therapy without improvement in the tem- 
perature curve. Because of the patient’s continuing febrile 
course as well as the established diagnosis of PSTT, the 
patient was transferred to the University of Michigan 
Medical Center (UMMC). Upon admission to the 
UMMC, the patient had nightly febrile episodes to 40°C 
which did not respond to ampicillin, tobramycin, and Fla- 
gyl antibiotic therapy. Multiple cultures from all sites 
failed to identify an infectious source. Pelvic examination 
revealed an enlarged uterus that was not involuting at the 
expected rate. The cervix appeared abnormal and mul- 
tiple nodules were palpated in the posterior vaginal wall. 
Biopsies of the cervix, as well as the vagina, showed 
PSTT. The source for the patient’s fever was thought to 
be a large amount of necrotic PSTT in the uterus. Three 
weeks following her cesarean section she was again sur- 
gically explored. At the time of this surgery, the patient’s 
abdomen was remarkably different from what had pre- 
viously been found. At the time of cesarean section, the 
abdomen was normal while at her second laparotomy the 
abdominal contents were visible with only a few adhe- 
sions. Three weeks later, generalized neoplastic spread 
was present. The entire small bowel was encased in neo- 
plasm. The neoplasm extended onto the liver and from 
the omentum along the entire length of the greater cur- 
vature of the stomach. The uterus and adnexa were com- 
pletely replaced with neoplasm and after extensive dis- 
section, a supracervical hysterectomy and bilateral 
salpingo-oophorectomy were performed. This was per- 
formed in the hope of removing a possibly infectious 
source for her fever. Biopsy of both the omentum and a 
thickened area in the previous abdominal incision showed 
PSTT. Postoperatively, the patient experienced contin- 
uing nightly fevers to 40-41°C. Her bowel function ini- 
tially returned 3 days postoperatively. However, on Post- 
operative Day 12, a complete bowel obstruction 
developed. Chemotherapy was begun consisting of meth- 
otrexate, actinomycin, VP-16, and c&platinum. Despite 
chemotherapy, the upper abdominal tumor mass enlarged 
by palpation. She received one cycle of chemotherapy, 
but due to a worsening performance status and the non- 
responsiveness of the tumor no further chemotherapy was 
administered. The patient continued on nasogastric suc- 
tion and central hyperalimentation until she died from 
progressive disease, 10 weeks from the time of her ce- 
sarean section. The patient’s family refused autopsy. 
Immediately postcesarean section, the patient’s serum 
HCG was 80 mIU/ml. This rapidly decreased to a non- 
detectable level 2 weeks after delivery and despite an 
extensive amount of tumor in her abdomen, her HCG 
remained nondetectable. Serum HPL was 0.3 pgm/ml 
with a normal range at 34 weeks gestational age of 3.9- 
13.0. Prehysterectomy, her CA-125 was 5360 u/ml (nor- 
mal, O-35) and 1 week after hysterectomy, 1645 u/ml. 
The patient’s blood type was 0, Rh negative and her 
husband was 0, Rh positive. 
PATHOLOGY 
The endometrial cavity of the 540-g partially involuted 
uterus was lined by a soft grey-tan neoplasm. Although 
the neoplasm covered the entire endometrial surface, it 
formed a prominent 4 x 4-cm mass on the posterior wall. 
This nodule was consistent with the ultrasound findings 
in late pregnancy. The tumor extended transmurally in 
several areas and involved both adnexa. 
Microscopically, the neoplasm was composed of sheets 
of polyhedral cells with large vesicular nuclei and eosin- 
ophilic to clear cytoplasm. Although occasional giant cells 
were noted, the majority of cells were intermediate in 
type with features of both cytotrophoblast and syncytio- 
trophoblast (Figs. 1,2). The dimorphic cell population 
characteristic of choriocarcinoma was not seen. The tu- 
mor exhibited a high mitotic rate, with as many as 15 
mitotic figures per single high-power field. The neoplastic 
cells spread extensively in cords and medullary nests be- 
tween fibers of smooth muscle within the myometrium. 
Extensive hemorrhage within the tumor was not noted. 
Extensive vascular and lymphatic invasion was seen in 
the myometrium and adnexa, including the ovaries. The 
omentum and abdominal wall contained the same neo- 
plasm. Immunohistochemical staining revealed that the 
tumor cells were diffusely positive for broad spectrum 
keratin. Five to ten percent was positive for placental 
alkaline phosphatase, slightly less (2-5%) was positive 
for HPL, and only rare cells were positive for HCG. 
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FIG. 1. Neoplasm diffuscly infiltrating myometrium (IO x ) 
The 14 x 14-cm 350-g discoid placenta had a para- 
marginal insertion of a three-vessel umbilical cord. The 
fetal surface was smooth, glistening, and grey-blue, with 
a normal vascular pattern. The membranes were focally 
thickened but still translucent with a marginal insertion. 
The maternal surface was composed of intact cotyledons, 
with one 4 x 4-cm area near one area which was thinned 
and covered by a grey-tan exudate. No grossly identifi- 
able tumor involved the placenta. 
Microscopic sections of the placenta revealed foci of 
partially necrotic tumor adherent to membrane but no 
tumor involved the placenta. The maternal surface of the 
placenta was intact. 
DISCUSSION 
PSTT is a rare tumor which is usually diagnosed at 
some interval after pregnancy. This is the first patient to 
our knowledge with PSTT and a viable pregnancy. The 
diagnosis was based on the morphologic features of the 
tumor cells, their pattern of infiltration of the myome- 
trium, the lack of extensive hemorrhage or intravascular 
growth, and the much higher percentage of cells positive 
for HPL compared to HCG. The posterior placenta was 
located over the necrotic nodule found at hysterectomy, 
suggesting that this was the site of origin. Additionally, 
the tumor extended to the placenta and onto the fetal 
membranes but was not intraamniotic. The low a-feto- 
protein early in pregnancy and the placental abruption 
most likely relate to an abnormal placentation. However, 
the infant was normally developed and of appropriate 
size for gestational age, indicating that she was able to 
maintain the necessary placental function to obtain a vi- 
able pregnancy. The infant appeared unaffected by the 
presence of the neoplasm and is developing normally. 
This patient and the patient reported by Finkler et al. 
who was 21 weeks gestational age demonstrate that as 
with trophoblastic disease, this entity can be associated 
with a viable fetus 151. The pregnancy reported here also 
resulted in a male infant (normal XY). A previous report 
summarizing the literature, associated PSTT with a pre- 
vious female infant [6]. This patient also had a previous 
female infant 2 years prior to conception. It is possible 
but unlikely that the PSTT was related to her prior preg- 
nancy as she resumed completely normal menses after 
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FIG. 2. Sheets of intermediate-type trophoblast cells include only a rare multinucleated giant cell. Extensive hemorrhage is not present (20 x ). 
her first pregnancy and experienced no interval abnormal 
bleeding. 
The spread of this patient’s neoplasm is in accordance 
with those of previously reported patients in whom the 
neoplasm can involve the cervix, vagina, ovaries, and 
intraabdominal structures. Following cesarean section, 
this neoplasm followed a most aggressive course, spread- 
ing throughout the abdomen, eventually leading to in- 
traabdominal spread and small bowel obstruction. She 
did not have an initial response to chemotherapy and 
rapidly followed a downhill course. The prediction of 
response to chemotherapy may lie in the presence or 
absence of HCG-producing trophoblast. The intermediate 
trophoblast of PSTI produces variable amounts of HCG 
and as reviewed by Lathrop, 6 of the 10 reported patients 
showed a partial response to the chemotherapy [6,13]. In 
a previous patient reported by Hopkins et al., when the 
HCG value was extremely high, the response to chemo- 
therapy was rather dramatic. Once the HCG reached 
lower levels, the response to chemotherapy then ceased 
[2]. In this patient, where HCG levels were nondetectable 
there appeared to be no response to chemotherapy. This 
may suggest that the trophoblast which is producing HCG 
is responsive to conventional chemotherapeutic agents 
and non-HCG-producing trophoblast is resistant. 
Elevated levels of serum CA-125 associated with preg- 
nancy have been reported. The levels appear to peak at 
approximately 10 weeks gestational age, return to normal, 
and then rise at the time of placental separation [14]. 
High concentrations of CA-125 are found in chorionic 
and decidual tissue extracts while amniotic and placental 
extracts lack CA-125 [15,16]. The extremely high levels 
in this patient suggest that the PSTI may have been 
associated with these elements of the placenta. It is pos- 
sible that CA-125 will become another tumor marker that 
can be used to follow the clinical course of this disease. 
The malignant form of PSTT appears to follow a very 
aggressive course. Young and Scully reported that this is 
related to the number of mitoses per 10 high-power fields 
[17]. This patient had extensive mitoses per high-power 
field with some fields having 15 mitoses per individual 
high-power field. In this young patient, metastatic PSTI 
followed a fulminate aggressive course. Other patients 
reported with metastatic PSTT have survived a period of 
months to years before succumbing to the disease. This 
patient had no response to chemotherapy and was never 
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able to leave the hospital. This patient’s more aggressive 
course may in part have been due to her altered immu- 
nologic status associated with the pregnancy. Like cho- 
riocarcinoma when PS?T is associated with a term preg- 
nancy, it may represent a high-risk situation. 
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